nitrofurantoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
NO2 - derivatives 1949 67-20-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nitrofurantoin sodium
  • nitrofurantoin
  • furadantin
  • furadantoin
  • nitrofurantoin, macrocrystalline
  • nitrofurantoin monohydrate
A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.
  • Molecular weight: 238.16
  • Formula: C8H6N4O5
  • CLOGP: -0.47
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 1
  • TPSA: 120.73
  • ALOGS: -2.76
  • ROTB: 3
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.08 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 47 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 24 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 87 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.57 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.70 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.17 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.97 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.455 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 2.748 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 21.184 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 5.821 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 61.090 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 33.130 % High 1
herg hERG pIC50 3.988 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 0.968 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.162 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 51.270 % High 1
kinase-safety-class ACVR2A,ACVR2B,ALK,AURKA,AURKB,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GRK3,GSK3B,ITK,JAK1,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK1,PDK2,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 48
kinase-selectivity-class AXL,CAMK2D,CDK9,DYRK1B,GRK2,GSK3A,GSK3B,HIPK2,IRAK1,MAP2K3,MAP2K6,MAP3K14,MAPK1,MAPK7,MARK4,PRKDC,SIK2,STK33,SYK,TEK,TTK,UHMK1 22
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 4.898 High 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.350 High 1
mh-clint Mouse hepatocyte intrinsic clearance 0.944 High 1
mppb Mouse plasma protein binding (% unbound) 73.050 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.349 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.69
pppb Pig plasma protein binding (% unbound) 44.040 % High 1
rat-kpuu-brain Rat brain Kpuu 0.272 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.291 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 95.690 % High 1
rppb Rat plasma protein binding (% unbound) 45.750 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 914.113 uM High 1

Approvals:

DateAgencyCompanyOrphan
Feb. 6, 1953 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 479.61 10.71 680 45622 304952 90277193
Autoimmune hepatitis 340.63 10.71 145 46157 10206 90571939
Jaundice 201.29 10.71 152 46150 32365 90549780
Swollen tongue 146.29 10.71 147 46155 45809 90536336
Pulmonary toxicity 139.88 10.71 82 46220 11449 90570696
Infusion related reaction 136.93 10.71 24 46278 416756 90165389
Synovitis 127.72 10.71 11 46291 329741 90252404
Glossodynia 123.90 10.71 11 46291 321768 90260377
Hand deformity 123.12 10.71 7 46295 296355 90285790
Cystitis 120.12 10.71 159 46143 66559 90515586
Interstitial lung disease 116.41 10.71 168 46134 76237 90505908
Contraindicated product administered 108.30 10.71 17 46285 320122 90262023
Systemic lupus erythematosus 104.31 10.71 28 46274 361868 90220277
Wound 100.45 10.71 17 46285 302963 90279182
Swelling face 100.10 10.71 162 46140 81190 90500955
Lip swelling 98.86 10.71 110 46192 38500 90543645
Therapeutic product effect decreased 93.29 10.71 15 46287 277556 90304589
Drug ineffective 92.98 10.71 379 45923 1383919 89198226
Drug-induced liver injury 87.74 10.71 162 46140 90156 90491989
Pericarditis 87.70 10.71 16 46286 270135 90312010
Folliculitis 87.47 10.71 4 46298 204349 90377796
Systemic inflammatory response syndrome 83.44 10.71 48 46254 6468 90575677
Arthropathy 82.59 10.71 42 46260 366200 90215945
Oesophageal spasm 81.42 10.71 38 46264 3323 90578822
Heart sounds 80.93 10.71 28 46274 1116 90581029
Drug hypersensitivity 78.76 10.71 454 45848 463155 90118990
Drug reaction with eosinophilia and systemic symptoms 78.64 10.71 103 46199 42655 90539490
Prolonged expiration 78.35 10.71 28 46274 1229 90580916
Oesophageal pain 77.64 10.71 40 46262 4334 90577811
Psoriatic arthropathy 77.48 10.71 12 46290 228323 90353822
Muscle injury 77.12 10.71 3 46299 176651 90405494
Hepatic enzyme increased 69.27 10.71 50 46252 360686 90221459
Liver function test abnormal 69.11 10.71 106 46196 50739 90531406
Irritable bowel syndrome 65.80 10.71 13 46289 207435 90374710
Change of bowel habit 65.36 10.71 29 46273 2254 90579891
Rheumatoid arthritis 64.88 10.71 54 46248 362560 90219585
Urine odour abnormal 63.74 10.71 42 46260 7202 90574943
Cardiac murmur 61.21 10.71 60 46242 18134 90564011
Dysuria 59.06 10.71 86 46216 39315 90542830
Impaired healing 58.82 10.71 23 46279 234176 90347969
Treatment failure 58.50 10.71 42 46260 303886 90278259
Discomfort 58.12 10.71 34 46268 274301 90307844
Type 2 diabetes mellitus 58.00 10.71 16 46286 203228 90378917
Hallucination 57.49 10.71 113 46189 65846 90516299
Helicobacter infection 54.20 10.71 24 46278 226826 90355319
Bladder disorder 52.99 10.71 44 46258 10728 90571417
Musculoskeletal stiffness 52.00 10.71 45 46257 296487 90285658
Rectal polyp 51.78 10.71 20 46282 1093 90581052
Swelling 49.84 10.71 86 46216 418972 90163173
Multiple sclerosis 49.55 10.71 66 46236 27774 90554371
Appetite disorder 48.49 10.71 39 46263 9094 90573051
Eosinophilia 48.28 10.71 66 46236 28467 90553678
Lymphoedema 47.48 10.71 46 46256 13707 90568438
Off label use 47.18 10.71 350 45952 1101902 89480243
Ill-defined disorder 46.68 10.71 18 46284 184873 90397272
Respiration abnormal 46.57 10.71 36 46266 7927 90574218
Intestinal haemorrhage 44.60 10.71 28 46274 4419 90577726
Gut fermentation syndrome 43.86 10.71 8 46294 16 90582129
Joint swelling 43.63 10.71 123 46179 503177 90078968
Angioedema 43.62 10.71 100 46202 64776 90517369
Depressive symptom 42.55 10.71 29 46273 5256 90576889
Blood cholesterol increased 42.35 10.71 27 46275 207985 90374160
Alopecia 42.17 10.71 122 46180 494949 90087196
Hydronephrosis 41.91 10.71 41 46261 12361 90569784
Tinnitus 41.44 10.71 77 46225 43025 90539120
Acute hepatic failure 40.94 10.71 54 46248 22507 90559638
Malaise 40.77 10.71 468 45834 585518 89996627
Urosepsis 40.37 10.71 52 46250 21180 90560965
Rales 40.34 10.71 45 46257 15782 90566363
Peripheral coldness 39.78 10.71 42 46260 13850 90568295
Chromaturia 39.67 10.71 49 46253 19138 90563007
Productive cough 39.40 10.71 107 46195 76956 90505189
Blister 38.60 10.71 44 46258 254954 90327191
Gallbladder disorder 38.44 10.71 49 46253 19754 90562391
Bursitis 36.38 10.71 11 46291 131643 90450502
Joint range of motion decreased 36.29 10.71 12 46290 135631 90446514
Frustration tolerance decreased 36.26 10.71 31 46271 7865 90574280
Sensitisation 36.23 10.71 24 46278 4151 90577994
Urinary incontinence 35.98 10.71 67 46235 37499 90544646
Prescribed overdose 35.81 10.71 4 46298 97621 90484524
Pollakiuria 35.61 10.71 62 46240 32943 90549202
Multiple sclerosis relapse 35.58 10.71 81 46221 52224 90529921
Myalgia 35.39 10.71 180 46122 174945 90407200
Wound infection 35.16 10.71 6 46296 106396 90475749
Drug intolerance 34.77 10.71 115 46187 447476 90134669
Urine abnormality 34.76 10.71 30 46272 7707 90574438
Facet joint syndrome 33.75 10.71 5 46297 98384 90483761
Sinusitis 33.42 10.71 79 46223 343009 90239136
Nightmare 33.40 10.71 48 46254 21677 90560468
Emotional distress 33.39 10.71 64 46238 36598 90545547
Therapy non-responder 33.38 10.71 14 46288 136690 90445455
Flank pain 33.33 10.71 45 46257 19177 90562968
Stress 32.96 10.71 104 46198 81291 90500854
Hypercholesterolaemia 32.66 10.71 6 46296 100886 90481259
Catarrh 32.09 10.71 16 46286 1618 90580527
Peripheral venous disease 31.91 10.71 3 46299 83918 90498227
Pulmonary embolism 31.91 10.71 142 46160 130678 90451467
Amblyopia 31.24 10.71 10 46292 312 90581833
C-reactive protein increased 31.21 10.71 28 46274 181361 90400784
Pyelonephritis 31.18 10.71 46 46256 21270 90560875
Weight increased 30.68 10.71 110 46192 417817 90164328
Adverse event 30.36 10.71 11 46291 117407 90464738
Infection 30.25 10.71 90 46212 362004 90220141
Hypersensitivity pneumonitis 30.22 10.71 21 46281 3927 90578218
Pneumonitis 29.60 10.71 68 46234 44102 90538043
Furuncle 29.37 10.71 27 46275 7534 90574611
Burns second degree 29.19 10.71 16 46286 1964 90580181
Tubulointerstitial nephritis 29.18 10.71 49 46253 25294 90556851
Hepatic fibrosis 29.16 10.71 21 46281 4154 90577991
Abdominal discomfort 29.16 10.71 135 46167 477193 90104952
General physical health deterioration 29.13 10.71 89 46213 355026 90227119
Polyp 29.12 10.71 27 46275 7617 90574528
Grip strength decreased 28.93 10.71 6 46296 92570 90489575
Injection site discomfort 28.67 10.71 24 46278 5916 90576229
Cholecystitis chronic 28.66 10.71 30 46272 9796 90572349
Gastrointestinal disorder 28.41 10.71 55 46247 256632 90325513
Chills 28.32 10.71 138 46164 131843 90450302
Pseudomembranous colitis 28.27 10.71 20 46282 3848 90578297
Nephrolithiasis 27.99 10.71 71 46231 49014 90533131
Vision blurred 27.87 10.71 121 46181 110172 90471973
Mass 27.83 10.71 37 46265 15540 90566605
Hiccups 27.73 10.71 18 46284 3008 90579137
Obesity 27.08 10.71 10 46292 105497 90476648
Kidney infection 27.07 10.71 48 46254 25868 90556277
Sciatica 27.07 10.71 9 46293 101373 90480772
Knee arthroplasty 26.81 10.71 5 46297 83177 90498968
Cough 26.65 10.71 297 46005 368665 90213480
Chest discomfort 26.41 10.71 140 46162 138225 90443920
Hyperhidrosis 26.07 10.71 138 46164 136167 90445978
Sleep apnoea syndrome 25.99 10.71 53 46249 31694 90550451
Feeling abnormal 25.88 10.71 160 46142 167075 90415070
Mobility decreased 25.82 10.71 56 46246 250678 90331467
Night sweats 25.81 10.71 17 46285 128749 90453396
Proctalgia 25.66 10.71 26 46276 8172 90573973
Hyponatraemia 25.41 10.71 135 46167 133403 90448742
Peripheral swelling 25.13 10.71 117 46185 412989 90169156
Sleep disorder 25.04 10.71 39 46263 197991 90384154
Dysphonia 24.99 10.71 80 46222 63004 90519141
Depressed mood 24.94 10.71 69 46233 50153 90531992
Gait inability 24.72 10.71 23 46279 146433 90435712
Therapeutic product effect incomplete 24.69 10.71 38 46264 193858 90388287
Steroid dependence 24.57 10.71 15 46287 2254 90579891
Neurogenic bladder 24.55 10.71 18 46284 3660 90578485
Liver transplant 24.28 10.71 15 46287 2302 90579843
Product use issue 24.09 10.71 87 46215 329832 90252313
Haematuria 23.64 10.71 54 46248 34883 90547262
Costovertebral angle tenderness 23.54 10.71 7 46295 170 90581975
Road traffic accident 23.26 10.71 13 46289 107613 90474532
Pharyngeal swelling 23.19 10.71 27 46275 9917 90572228
Agitation 22.95 10.71 81 46221 67017 90515128
Cystitis interstitial 22.88 10.71 13 46289 1711 90580434
Postoperative wound infection 22.63 10.71 31 46271 13395 90568750
Cystitis bacterial 22.56 10.71 8 46294 343 90581802
Drug abuse 22.53 10.71 7 46295 82340 90499805
Fibromyalgia 22.13 10.71 45 46257 206224 90375921
Musculoskeletal discomfort 22.08 10.71 39 46263 20952 90561193
Intentional product use issue 21.87 10.71 49 46253 216843 90365302
Abdominal pain 21.47 10.71 302 46000 395419 90186726
Atrioventricular block first degree 21.35 10.71 24 46278 8487 90573658
Hepatic necrosis 21.22 10.71 21 46281 6417 90575728
Fracture displacement 20.90 10.71 11 46291 1245 90580900
Duodenal ulcer 20.73 10.71 25 46277 9527 90572618
Therapeutic response decreased 20.63 10.71 10 46292 89719 90492426
Bone disorder 20.61 10.71 40 46262 23080 90559065
Syncope 20.57 10.71 127 46175 132536 90449609
Nail infection 20.44 10.71 14 46288 2558 90579587
Anhedonia 20.18 10.71 27 46275 11404 90570741
Weight decreased 19.84 10.71 288 46014 379622 90202523
Forced vital capacity abnormal 19.81 10.71 5 46297 64 90582081
Hepatitis acute 19.66 10.71 26 46276 10861 90571284
Rash macular 19.61 10.71 46 46256 30234 90551911
Hypopnoea 19.54 10.71 17 46285 4414 90577731
Tendinous contracture 19.43 10.71 6 46296 166 90581979
Vascular device infection 19.25 10.71 27 46275 11925 90570220
Nasal congestion 19.18 10.71 89 46213 83325 90498820
Hepatic failure 19.15 10.71 54 46248 39674 90542471
Upper respiratory tract congestion 19.11 10.71 13 46289 2349 90579796
Acute lung injury 19.09 10.71 11 46291 1487 90580658
Pneumonia viral 19.00 10.71 23 46279 8800 90573345
Acute febrile neutrophilic dermatosis 18.52 10.71 15 46287 3530 90578615
Maternal exposure during pregnancy 18.50 10.71 108 46194 359955 90222190
Injection site mass 18.23 10.71 37 46265 22053 90560092
Haemolysis 18.02 10.71 22 46280 8488 90573657
Hypertension 17.73 10.71 149 46153 457383 90124762
Fall 17.73 10.71 345 45957 481465 90100680
Hepatic encephalopathy 17.71 10.71 28 46274 13744 90568401
Pseudophaeochromocytoma 17.45 10.71 5 46297 106 90582039
Thyroid disorder 17.38 10.71 32 46270 17753 90564392
Dyspnoea 17.35 10.71 580 45722 880375 89701770
Pulmonary fibrosis 17.35 10.71 104 46198 107399 90474746
Traumatic lung injury 17.24 10.71 11 46291 1785 90580360
Mental status changes 17.09 10.71 56 46246 44623 90537522
Urinary retention 16.93 10.71 50 46252 37694 90544451
Shunt infection 16.71 10.71 5 46297 124 90582021
Oesophageal cancer metastatic 16.49 10.71 5 46297 130 90582015
Neuropathy peripheral 16.38 10.71 123 46179 136847 90445298
Hepatitis cholestatic 16.32 10.71 21 46281 8540 90573605
Urinary tract infection bacterial 16.24 10.71 18 46284 6267 90575878
Chronic hepatitis 16.19 10.71 9 46293 1136 90581009
Needle issue 16.12 10.71 27 46275 13907 90568238
Cholelithiasis 15.95 10.71 61 46241 52445 90529700
Palpitations 15.91 10.71 122 46180 136606 90445539
Colour blindness acquired 15.90 10.71 5 46297 147 90581998
Angina pectoris 15.81 10.71 50 46252 39110 90543035
Coagulopathy 15.76 10.71 36 46266 23253 90558892
Myelosuppression 15.69 10.71 4 46298 53587 90528558
Ureteric obstruction 15.59 10.71 11 46291 2107 90580038
Bladder irritation 15.48 10.71 6 46296 331 90581814
Breath sounds abnormal 15.43 10.71 28 46274 15358 90566787
Osteoarthritis 15.37 10.71 50 46252 195680 90386465
Retroperitoneal fibrosis 15.36 10.71 6 46296 338 90581807
Jaundice cholestatic 15.16 10.71 22 46280 10021 90572124
Febrile neutropenia 14.98 10.71 37 46265 158312 90423833
Poor peripheral circulation 14.91 10.71 14 46288 4011 90578134
Lower limb fracture 14.76 10.71 13 46289 85000 90497145
Lichen sclerosus 14.73 10.71 9 46293 1354 90580791
Blood alkaline phosphatase increased 14.72 10.71 56 46246 48023 90534122
Autonomic dysreflexia 14.69 10.71 6 46296 380 90581765
Nausea 14.64 10.71 700 45602 1109616 89472529
Rash 14.62 10.71 520 45782 795580 89786565
Acarodermatitis 14.59 10.71 9 46293 1377 90580768
Arthralgia 14.40 10.71 296 46006 778226 89803919
International normalised ratio increased 14.40 10.71 55 46247 47261 90534884
Gingival pain 14.36 10.71 21 46281 9631 90572514
Subacute cutaneous lupus erythematosus 14.32 10.71 13 46289 3569 90578576
Autoimmune disorder 14.24 10.71 11 46291 76733 90505412
Chronic kidney disease 14.19 10.71 57 46245 50134 90532011
Hip arthroplasty 14.04 10.71 11 46291 76197 90505948
Overdose 14.03 10.71 38 46264 157671 90424474
Condition aggravated 14.00 10.71 217 46085 595328 89986817
Abdominal rigidity 13.92 10.71 11 46291 2501 90579644
Red blood cell sedimentation rate increased 13.90 10.71 13 46289 82582 90499563
Feeling cold 13.90 10.71 38 46264 27427 90554718
Tendon pain 13.82 10.71 13 46289 3735 90578410
Lung neoplasm malignant 13.72 10.71 35 46267 24238 90557907
Reperfusion arrhythmia 13.68 10.71 5 46297 234 90581911
Escherichia urinary tract infection 13.68 10.71 25 46277 13790 90568355
Psoriasis 13.60 10.71 35 46267 147719 90434426
Clostridium difficile colitis 13.56 10.71 37 46265 26669 90555476
Mouth ulceration 13.45 10.71 48 46254 39926 90542219
Micturition urgency 13.31 10.71 22 46280 11211 90570934
Throat tightness 13.17 10.71 39 46263 29445 90552700
Deep vein thrombosis 13.14 10.71 86 46216 91534 90490611
Catheter site mass 13.05 10.71 3 46299 25 90582120
Pyrexia 13.02 10.71 435 45867 660050 89922095
Lower urinary tract symptoms 12.98 10.71 4 46298 110 90582035
Parosmia 12.95 10.71 17 46285 7052 90575093
Leukocytosis 12.91 10.71 40 46262 30950 90551195
Dysbiosis 12.90 10.71 9 46293 1693 90580452
Alanine aminotransferase increased 12.89 10.71 104 46198 118234 90463911
Dizziness 12.89 10.71 393 45909 588891 89993254
Product contamination microbial 12.81 10.71 5 46297 281 90581864
Lung consolidation 12.75 10.71 14 46288 4826 90577319
Laryngitis 12.71 10.71 5 46297 50748 90531397
Fluid intake reduced 12.69 10.71 13 46289 4139 90578006
Traumatic liver injury 12.51 10.71 5 46297 299 90581846
Coagulation factor X level abnormal 12.14 10.71 3 46299 35 90582110
Lethargy 12.12 10.71 64 46238 63075 90519070
Bone erosion 12.05 10.71 6 46296 53015 90529130
Organising pneumonia 11.99 10.71 17 46285 7580 90574565
Back pain 11.95 10.71 228 46074 316947 90265198
Urine analysis abnormal 11.88 10.71 14 46288 5207 90576938
Coeliac disease 11.84 10.71 4 46298 44606 90537539
Eosinophilic pleural effusion 11.64 10.71 4 46298 156 90581989
Genital burning sensation 11.55 10.71 5 46297 366 90581779
Rhinitis 11.52 10.71 23 46279 13549 90568596
Retinopathy of prematurity 11.51 10.71 5 46297 369 90581776
Anaemia neonatal 11.50 10.71 5 46297 370 90581775
Bronchiectasis 11.40 10.71 31 46271 22299 90559846
Hip fracture 11.37 10.71 40 46262 33037 90549108
Ocular icterus 11.34 10.71 12 46290 3968 90578177
Feelings of worthlessness 11.22 10.71 5 46297 393 90581752
Hepatitis 11.13 10.71 68 46234 70671 90511474
Tracheo-oesophageal fistula 11.07 10.71 6 46296 720 90581425
Back injury 11.02 10.71 5 46297 46617 90535528
Blood creatinine decreased 10.91 10.71 15 46287 6500 90575645
Accidental exposure to product 10.89 10.71 4 46298 42362 90539783
Heart rate decreased 10.80 10.71 55 46247 53450 90528695
Reflexes abnormal 10.75 10.71 6 46296 763 90581382
Neuralgia 10.75 10.71 38 46264 31462 90550683
Nasopharyngitis 10.72 10.71 145 46157 406959 90175186

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cardiac murmur 203.20 18.93 86 10258 12689 42598302
Catarrh 202.93 18.93 70 10274 5916 42605075
Burns second degree 201.68 18.93 70 10274 6026 42604965
Steroid dependence 191.23 18.93 69 10275 6653 42604338
Hypopnoea 184.13 18.93 70 10274 7812 42603179
Gingival pain 182.58 18.93 71 10273 8423 42602568
Parosmia 182.18 18.93 69 10275 7622 42603369
Systemic lupus erythematosus 172.72 18.93 70 10274 9254 42601737
Rhinitis 152.65 18.93 69 10275 11908 42599083
Impaired work ability 148.86 18.93 68 10276 12023 42598968
Alcohol poisoning 140.74 18.93 57 10287 7517 42603474
Bronchiectasis 128.69 18.93 70 10274 17949 42593042
Nightmare 124.93 18.93 77 10267 24935 42586056
Swollen tongue 123.24 18.93 72 10272 21159 42589832
Frequent bowel movements 120.06 18.93 71 10273 21336 42589655
Impaired quality of life 112.26 18.93 59 10285 14118 42596873
Colitis ulcerative 109.36 18.93 72 10272 26103 42584888
Migraine 106.41 18.93 70 10274 25344 42585647
Tubulointerstitial nephritis 104.02 18.93 75 10269 31473 42579518
Tinnitus 102.81 18.93 72 10272 28866 42582125
Eczema 101.05 18.93 76 10268 34010 42576981
Vertigo 100.53 18.93 76 10268 34271 42576720
Accidental overdose 99.51 18.93 70 10274 28260 42582731
Dysgeusia 98.63 18.93 75 10269 34114 42576877
Medication error 98.45 18.93 74 10270 33080 42577911
Urinary tract infection 83.02 18.93 111 10233 99173 42511818
Palpitations 82.16 18.93 80 10264 50717 42560274
Rectal haemorrhage 81.88 18.93 79 10265 49527 42561464
Stress 77.89 18.93 73 10271 44139 42566852
Abdominal discomfort 76.91 18.93 93 10251 75162 42535829
Arthritis 75.15 18.93 70 10274 41995 42568996
Loss of personal independence in daily activities 72.34 18.93 74 10270 49742 42561249
Adverse drug reaction 66.29 18.93 62 10282 37372 42573619
Exposure during pregnancy 66.02 18.93 35 10309 8513 42602478
Deep vein thrombosis 64.22 18.93 86 10258 76871 42534120
Haematochezia 60.96 18.93 73 10271 58363 42552628
Intentional product use issue 46.28 18.93 71 10273 71762 42539229
Somnolence 43.79 18.93 102 10242 141003 42469988
Pulmonary embolism 43.34 18.93 92 10252 119520 42491471
Cerebrovascular accident 42.70 18.93 81 10263 97079 42513912
Inappropriate schedule of product administration 39.75 18.93 78 10266 95824 42515167
Confusional state 37.38 18.93 107 10237 167490 42443501
Depression 35.07 18.93 81 10263 111282 42499709
Rash 33.22 18.93 144 10200 276810 42334181
Urosepsis 28.75 18.93 26 10318 14994 42595997
Prostatitis 28.06 18.93 18 10326 6230 42604761
Culture urine positive 27.48 18.93 11 10333 1404 42609587
Protein total abnormal 27.30 18.93 8 10336 397 42610594
Open reduction of fracture 26.80 18.93 6 10338 99 42610892
Pulmonary valve stenosis 26.64 18.93 8 10336 432 42610559
Mixed anxiety and depressive disorder 26.50 18.93 7 10337 236 42610755
Weight decreased 26.35 18.93 110 10234 207838 42403153
Skin depigmentation 26.15 18.93 8 10336 460 42610531
COVID-19 25.79 18.93 74 10270 115874 42495117
Pain in extremity 22.56 18.93 84 10260 150520 42460471
Death 22.37 18.93 51 10293 471134 42139857
Porphyria non-acute 21.59 18.93 7 10337 487 42610504
Breast inflammation 20.86 18.93 4 10340 29 42610962
Tendonitis 20.67 18.93 18 10326 9876 42601115
Pulmonary toxicity 20.66 18.93 17 10327 8638 42602353
Sulphaemoglobinaemia 19.90 18.93 4 10340 38 42610953
Hair colour changes 19.83 18.93 10 10334 2192 42608799
Haematuria 19.24 18.93 43 10301 57756 42553235

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 458.39 11.60 644 49027 325638 110213990
Autoimmune hepatitis 302.61 11.60 143 49528 14661 110524967
Swollen tongue 253.52 11.60 213 49458 60149 110479479
Catarrh 191.40 11.60 84 49587 7251 110532377
Burns second degree 183.96 11.60 83 49588 7650 110531978
Steroid dependence 173.66 11.60 82 49589 8387 110531241
Cardiac murmur 163.10 11.60 114 49557 24514 110515114
Pulmonary toxicity 161.00 11.60 100 49571 17646 110521982
Hypopnoea 156.32 11.60 84 49587 11296 110528332
Parosmia 147.45 11.60 85 49586 13095 110526533
Drug-induced liver injury 140.71 11.60 218 49453 119849 110419779
Gingival pain 138.53 11.60 87 49584 15649 110523979
Jaundice 136.19 11.60 150 49521 59086 110480542
Tinnitus 123.36 11.60 144 49527 60396 110479232
Swelling face 121.53 11.60 177 49494 92144 110447484
Nightmare 117.48 11.60 114 49557 38749 110500879
Lip swelling 114.22 11.60 127 49544 50540 110489088
Rhinitis 110.31 11.60 87 49584 22458 110517170
Cystitis 108.60 11.60 141 49530 65895 110473733
Alcohol poisoning 105.80 11.60 60 49611 8960 110530668
Infusion related reaction 98.32 11.60 25 49646 381137 110158491
Impaired work ability 98.25 11.60 87 49584 26332 110513296
Oesophageal spasm 95.70 11.60 42 49629 3624 110536004
Bronchiectasis 93.71 11.60 98 49573 36395 110503233
Synovitis 93.37 11.60 8 49663 274084 110265544
Stress 89.81 11.60 166 49505 105182 110434446
Tubulointerstitial nephritis 89.40 11.60 116 49555 54168 110485460
Oesophageal pain 85.20 11.60 43 49628 5082 110534546
Interstitial lung disease 84.87 11.60 191 49480 139143 110400485
Urine odour abnormal 83.42 11.60 48 49623 7367 110532261
Heart sounds 80.51 11.60 27 49644 1116 110538512
Hand deformity 72.74 11.60 7 49664 218499 110321129
Impaired quality of life 72.44 11.60 78 49593 29939 110509689
Prolonged expiration 72.44 11.60 27 49644 1525 110538103
Accidental overdose 72.03 11.60 102 49569 51732 110487896
Systemic inflammatory response syndrome 71.82 11.60 54 49617 12989 110526639
Rash 69.99 11.60 617 49054 820347 109719281
Palpitations 68.30 11.60 191 49480 159021 110380607
Liver function test abnormal 68.23 11.60 116 49555 68834 110470794
Glossodynia 66.80 11.60 10 49661 221994 110317634
Drug hypersensitivity 64.54 11.60 386 49285 453704 110085924
Drug reaction with eosinophilia and systemic symptoms 63.34 11.60 124 49547 81971 110457657
Eczema 62.97 11.60 115 49556 72178 110467450
Change of bowel habit 62.60 11.60 29 49642 2840 110536788
Dysgeusia 60.54 11.60 111 49560 69874 110469754
Folliculitis 59.61 11.60 4 49667 167649 110371979
Lymphoedema 59.20 11.60 51 49620 14878 110524750
Contraindicated product administered 58.97 11.60 19 49652 248248 110291380
Psoriatic arthropathy 58.88 11.60 9 49662 196752 110342876
Drug abuse 58.22 11.60 6 49665 177405 110362223
Urosepsis 57.59 11.60 70 49601 30605 110509023
Therapeutic product effect decreased 57.50 11.60 19 49652 244297 110295331
Wound 57.38 11.60 17 49654 234420 110305208
Vertigo 57.31 11.60 123 49548 86747 110452881
Bladder disorder 56.69 11.60 44 49627 11093 110528535
Dysuria 56.54 11.60 99 49572 60132 110479496
Pulmonary embolism 56.52 11.60 218 49453 214256 110325372
Hallucination 55.13 11.60 133 49538 101299 110438329
Off label use 54.04 11.60 424 49247 1499761 109039867
Drug ineffective 53.74 11.60 432 49239 1520108 109019520
Pericarditis 53.42 11.60 16 49655 219098 110320530
Deep vein thrombosis 50.62 11.60 158 49513 139729 110399899
Treatment failure 50.50 11.60 31 49640 277203 110262425
Malaise 49.67 11.60 490 49181 671329 109868299
Rectal polyp 47.98 11.60 20 49651 1520 110538108
Arthropathy 47.24 11.60 36 49635 287486 110252142
Rheumatoid arthritis 46.13 11.60 40 49631 299573 110240055
Irritable bowel syndrome 45.87 11.60 9 49662 164206 110375422
Respiration abnormal 44.04 11.60 36 49635 9773 110529855
Multiple sclerosis 44.01 11.60 56 49615 25642 110513986
Hypersensitivity pneumonitis 43.57 11.60 28 49643 5237 110534391
Type 2 diabetes mellitus 43.09 11.60 13 49658 177219 110362409
Pulmonary fibrosis 42.36 11.60 121 49550 101921 110437707
Appetite disorder 42.08 11.60 35 49636 9734 110529894
Gut fermentation syndrome 41.22 11.60 8 49663 30 110539598
Febrile neutropenia 41.13 11.60 49 49622 316718 110222910
Death 41.10 11.60 168 49503 698701 109840927
Weight decreased 40.39 11.60 353 49318 467704 110071924
Hepatic enzyme increased 39.20 11.60 52 49619 320840 110218788
Sensitisation 39.19 11.60 24 49647 4127 110535501
Frustration tolerance decreased 39.11 11.60 32 49639 8699 110530929
Headache 37.53 11.60 580 49091 881797 109657831
Angioedema 37.25 11.60 113 49558 98387 110441241
Impaired healing 37.23 11.60 21 49650 196696 110342932
Gallbladder disorder 36.28 11.60 46 49625 20983 110518645
C-reactive protein increased 36.16 11.60 27 49644 217892 110321736
Frequent bowel movements 36.02 11.60 91 49580 71299 110468329
Weight increased 35.11 11.60 86 49585 419558 110120070
Colitis ulcerative 34.33 11.60 94 49577 77269 110462359
Mass 33.96 11.60 43 49628 19587 110520041
Ill-defined disorder 33.86 11.60 14 49657 156839 110382789
Intestinal haemorrhage 33.08 11.60 27 49644 7314 110532314
Acute hepatic failure 33.01 11.60 59 49612 36409 110503219
Chromaturia 32.55 11.60 52 49619 29308 110510320
Hydronephrosis 32.22 11.60 43 49628 20622 110519006
Depressive symptom 31.86 11.60 28 49643 8386 110531242
Musculoskeletal stiffness 31.54 11.60 48 49623 279774 110259854
Flank pain 31.37 11.60 45 49626 23085 110516543
Medication error 30.99 11.60 111 49560 105255 110434373
Arthritis 30.86 11.60 153 49518 167433 110372195
Bursitis 30.74 11.60 10 49661 129908 110409720
Loss of personal independence in daily activities 30.55 11.60 141 49530 149879 110389749
Blood cholesterol increased 30.52 11.60 23 49648 184762 110354866
Eosinophilia 30.44 11.60 75 49596 57861 110481767
Migraine 30.40 11.60 155 49516 171497 110368131
Neutropenia 30.38 11.60 78 49593 374542 110165086
Urine abnormality 29.99 11.60 28 49643 9068 110530560
Hypercholesterolaemia 29.98 11.60 3 49668 90834 110448794
Facet joint syndrome 29.96 11.60 4 49667 96824 110442804
Feeling abnormal 29.82 11.60 160 49511 180551 110359077
Pyelonephritis 29.76 11.60 46 49625 25204 110514424
Peripheral coldness 29.55 11.60 39 49632 18501 110521127
Therapy non-responder 29.47 11.60 17 49654 157290 110382338
Anaemia 29.39 11.60 136 49535 546950 109992678
Furuncle 29.19 11.60 27 49644 8641 110530987
Rales 29.06 11.60 45 49626 24694 110514934
Amblyopia 29.04 11.60 9 49662 288 110539340
Depression 28.74 11.60 242 49429 317093 110222535
Prescribed overdose 28.63 11.60 3 49668 87578 110452050
Helicobacter infection 28.33 11.60 24 49647 181853 110357775
Injection site discomfort 28.21 11.60 24 49647 6883 110532745
Discomfort 27.03 11.60 34 49637 214673 110324955
Swelling 27.01 11.60 75 49596 350966 110188662
Cerebrovascular accident 26.91 11.60 156 49515 181128 110358500
Adverse drug reaction 26.73 11.60 106 49565 105453 110434175
Culture urine positive 26.72 11.60 20 49651 4776 110534852
Myelosuppression 26.70 11.60 5 49666 94335 110445293
Therapeutic product effect incomplete 26.58 11.60 37 49634 223768 110315860
Adverse event 26.41 11.60 8 49663 108801 110430827
Pollakiuria 26.23 11.60 60 49611 44135 110495493
Vision blurred 26.07 11.60 121 49550 128901 110410727
Cleft palate 26.06 11.60 9 49662 407 110539221
Polyp 25.97 11.60 27 49644 9953 110529675
Productive cough 25.96 11.60 111 49560 114194 110425434
Haematuria 25.75 11.60 89 49582 82916 110456712
Wound infection 25.48 11.60 6 49665 96459 110443169
Multiple sclerosis relapse 25.30 11.60 64 49607 50176 110489452
Cholecystitis chronic 25.26 11.60 26 49645 9474 110530154
Sleep apnoea syndrome 25.22 11.60 56 49615 40391 110499237
Hepatic fibrosis 25.01 11.60 24 49647 8042 110531586
Peripheral venous disease 24.81 11.60 4 49667 84113 110455515
Sinusitis 24.64 11.60 61 49610 296627 110243001
Urinary incontinence 24.58 11.60 62 49609 48525 110491103
Joint range of motion decreased 24.53 11.60 12 49659 121820 110417808
Rectal haemorrhage 23.93 11.60 112 49559 119721 110419907
General physical health deterioration 23.87 11.60 104 49567 425191 110114437
Pseudomembranous colitis 23.67 11.60 21 49650 6370 110533258
Neurogenic bladder 23.56 11.60 19 49652 5060 110534568
Emotional distress 23.50 11.60 58 49613 44789 110494839
Pharyngeal swelling 23.47 11.60 28 49643 12004 110527624
Fracture displacement 23.45 11.60 12 49659 1460 110538168
Infection 23.22 11.60 84 49587 362116 110177512
Depressed mood 23.21 11.60 70 49601 60739 110478889
Urinary tract infection bacterial 23.13 11.60 23 49648 8044 110531584
Obesity 23.07 11.60 11 49660 113340 110426288
Nail infection 22.51 11.60 14 49657 2474 110537154
Vascular device infection 22.21 11.60 32 49639 16480 110523148
Costovertebral angle tenderness 21.99 11.60 7 49664 245 110539383
Overdose 21.91 11.60 45 49626 233749 110305879
Hypertension 21.75 11.60 137 49534 509947 110029681
COVID-19 21.71 11.60 186 49485 244874 110294754
Chest discomfort 21.65 11.60 143 49528 173705 110365923
Dysphonia 21.49 11.60 79 49592 75850 110463778
Myalgia 21.42 11.60 172 49499 222209 110317419
Hepatitis acute 20.48 11.60 33 49638 18733 110520895
Gait inability 20.03 11.60 19 49652 136357 110403271
Intentional overdose 20.01 11.60 18 49653 132483 110407145
Tendon pain 19.95 11.60 19 49652 6307 110533321
Proctalgia 19.83 11.60 27 49644 13195 110526433
Femur fracture 19.69 11.60 54 49617 44415 110495213
Disease progression 19.62 11.60 51 49620 243983 110295645
Road traffic accident 19.56 11.60 12 49659 107386 110432242
Blister 19.47 11.60 46 49625 227330 110312298
Postoperative wound infection 18.99 11.60 29 49642 15724 110523904
Bone disorder 18.81 11.60 34 49637 21158 110518470
Mixed anxiety and depressive disorder 18.77 11.60 8 49663 643 110538985
Sciatica 18.76 11.60 9 49662 92390 110447238
Therapeutic response decreased 18.69 11.60 10 49661 96489 110443139
Toxicity to various agents 18.51 11.60 133 49538 480422 110059206
Tendonitis 18.44 11.60 38 49633 26045 110513583
Gastrointestinal disorder 18.38 11.60 52 49619 241900 110297728
Prostatitis 18.23 11.60 16 49655 4785 110534843
Cystitis interstitial 17.81 11.60 10 49661 1464 110538164
Haematochezia 17.52 11.60 100 49571 115424 110424204
Musculoskeletal discomfort 17.48 11.60 35 49636 23503 110516125
Autonomic dysreflexia 17.32 11.60 7 49664 492 110539136
Pneumonitis 17.13 11.60 74 49597 76457 110463171
Pseudophaeochromocytoma 17.12 11.60 5 49666 130 110539498
Lichen sclerosus 17.11 11.60 9 49662 1159 110538469
Night sweats 17.09 11.60 21 49650 133962 110405666
Pneumonia viral 17.06 11.60 23 49648 11134 110528494
Tendinous contracture 16.93 11.60 6 49665 293 110539335
Joint swelling 16.84 11.60 123 49548 442722 110096906
Liver transplant 16.84 11.60 15 49656 4574 110535054
Colour blindness acquired 16.57 11.60 5 49666 146 110539482
Chills 16.53 11.60 144 49527 190436 110349192
Throat tightness 16.18 11.60 42 49629 33447 110506181
Chronic hepatitis 16.11 11.60 10 49661 1762 110537866
Thyroid disorder 16.06 11.60 28 49643 16941 110522687
Hepatic necrosis 16.01 11.60 21 49650 9901 110529727
Hyperhidrosis 15.98 11.60 141 49530 187157 110352471
Poor peripheral circulation 15.96 11.60 14 49657 4183 110535445
Duodenal ulcer 15.68 11.60 30 49641 19484 110520144
Nephrolithiasis 15.58 11.60 65 49606 66147 110473481
Pyrexia 15.55 11.60 520 49151 897745 109641883
White blood cells urine positive 15.49 11.60 18 49653 7506 110532122
Kidney infection 15.47 11.60 35 49636 25564 110514064
Injection site mass 15.26 11.60 34 49637 24579 110515049
Mobility decreased 15.25 11.60 55 49616 237367 110302261
Bladder irritation 15.16 11.60 6 49665 399 110539229
Genital burning sensation 15.10 11.60 6 49665 403 110539225
Forced vital capacity abnormal 15.09 11.60 4 49667 72 110539556
Cough 15.05 11.60 291 49380 461350 110078278
Hepatic failure 15.03 11.60 66 49605 68673 110470955
Traumatic lung injury 14.93 11.60 11 49660 2566 110537062
Nasal congestion 14.85 11.60 85 49586 98197 110441431
Suprapubic pain 14.60 11.60 8 49663 1117 110538511
Urinary retention 14.55 11.60 66 49605 69617 110470011
Porphyria non-acute 14.51 11.60 7 49664 750 110538878
Suicide attempt 14.50 11.60 15 49656 103379 110436249
Dry mouth 14.44 11.60 44 49627 199904 110339724
Hypotension 14.43 11.60 158 49513 523691 110015937
Malignant neoplasm progression 14.40 11.60 36 49635 174531 110365097
Atrioventricular block first degree 14.16 11.60 24 49647 14201 110525427
Osteoarthritis 14.05 11.60 39 49632 182584 110357044
Acute febrile neutrophilic dermatosis 14.02 11.60 14 49657 4922 110534706
Drug intolerance 14.01 11.60 116 49555 406396 110133232
Psoriasis 13.93 11.60 26 49645 139967 110399661
Intentional product misuse 13.84 11.60 24 49647 132880 110406748
Needle issue 13.82 11.60 27 49644 17813 110521815
Cystitis bacterial 13.80 11.60 8 49663 1245 110538383
Calculus bladder 13.66 11.60 9 49662 1755 110537873
Fungal cystitis 13.66 11.60 3 49668 23 110539605
Product use issue 13.64 11.60 83 49588 311612 110228016
Somnolence 13.54 11.60 198 49473 297251 110242377
Shunt infection 13.45 11.60 5 49666 280 110539348
Open reduction of fracture 13.44 11.60 5 49666 281 110539347
Upper respiratory tract congestion 13.39 11.60 11 49660 3006 110536622
Incorrect route of product administration 13.37 11.60 6 49665 64055 110475573
Urine leukocyte esterase positive 13.15 11.60 12 49659 3774 110535854
Ureteric obstruction 13.09 11.60 11 49660 3103 110536525
Reperfusion arrhythmia 12.98 11.60 5 49666 309 110539319
Optic disc disorder 12.97 11.60 4 49667 126 110539502
Oesophageal cancer metastatic 12.94 11.60 5 49666 312 110539316
Lower limb fracture 12.93 11.60 9 49662 75339 110464289
Cardio-respiratory arrest 12.92 11.60 20 49651 115816 110423812
Feeling cold 12.85 11.60 39 49632 33948 110505680
Acarodermatitis 12.72 11.60 9 49662 1972 110537656
Coagulation factor X level abnormal 12.60 11.60 3 49668 34 110539594
Lactic acidosis 12.42 11.60 14 49657 92797 110446831
Back injury 12.41 11.60 3 49668 47396 110492232
Jaundice cholestatic 12.41 11.60 23 49648 14585 110525043
Illness 12.37 11.60 71 49600 82100 110457528
Dysbiosis 12.12 11.60 9 49662 2123 110537505
Sleep disorder 12.11 11.60 47 49624 198597 110341031
Escherichia urinary tract infection 11.96 11.60 24 49647 16138 110523490
Tracheo-oesophageal fistula 11.94 11.60 6 49665 703 110538925
Confusional state 11.91 11.60 285 49386 468395 110071233
Urine analysis abnormal 11.76 11.60 15 49656 6882 110532746
Hepatitis cholestatic 11.73 11.60 25 49646 17541 110522087
Vasculitic rash 11.67 11.60 9 49662 2248 110537380
Bone pain 11.65 11.60 59 49612 65074 110474554
Protein total abnormal 11.63 11.60 6 49665 742 110538886
Breast inflammation 11.62 11.60 4 49667 179 110539449

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01XE01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Nitrofuran derivatives
ATC J01XE51 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER ANTIBACTERIALS
Nitrofuran derivatives
FDA CS M0014892 Nitrofurans
FDA EPC N0000175494 Nitrofuran Antibacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000892 Anti-Infective Agents, Urinary
MeSH PA D000900 Anti-Bacterial Agents
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:36047 antibacterial drug
CHEBI has role CHEBI:50908 hepatotoxic agent

Related Drugs by ATC class:

J01XE Nitrofuran derivatives 2 drugs
furazidinnifurtoinol

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Klebsiella cystitis indication 60867007
Escherichia coli urinary tract infection indication 301011002
Staphylococcus Saprophyticus Urinary Tract Infection indication
Enterobacter Cystitis indication
Enterococcus Urinary Tract Infection indication
Staphylococcus Aureus Urinary Tract Infection indication
Prevention of Bacterial Urinary Tract Infection off-label use
Anuria contraindication 2472002 DOID:2983
Acute hepatitis contraindication 37871000
Vitamin B deficiency contraindication 47903000
Fibrosis of lung contraindication 51615001 DOID:3770
Obstructive hyperbilirubinemia contraindication 59848001
Interstitial pneumonia contraindication 64667001
Optic neuritis contraindication 66760008 DOID:1210
Diabetes mellitus contraindication 73211009 DOID:9351
Chronic hepatitis contraindication 76783007 DOID:2237
Oliguria contraindication 83128009
Cholestatic hepatitis contraindication 95556007
Anemia due to enzyme deficiency contraindication 111577008
Deficiency of glucose-6-phosphate dehydrogenase contraindication 124134002 DOID:2862
Cobalamin deficiency contraindication 190634004
Impaired renal function disorder contraindication 197663003
Drug-induced hepatitis contraindication 235876009
Peripheral nerve disease contraindication 302226006
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.28 acidic
pKa2 0.0 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucose-6-phosphate 1-dehydrogenase Enzyme WOMBAT-PK
CDGSH iron-sulfur domain-containing protein 1 Membrane other Ki 6.09 CHEMBL
Mitochondrial pyruvate carrier 2 Transporter INHIBITOR IC50 5.48 IUPHAR
Mitochondrial pyruvate carrier 1-like protein Transporter INHIBITOR IC50 5.48 IUPHAR

External reference:

IDSource
4018849 VUID
N0000147151 NUI
D00439 KEGG_DRUG
54-87-5 SECONDARY_CAS_RN
17140-81-7 SECONDARY_CAS_RN
4018848 VANDF
4018849 VANDF
C0028156 UMLSCUI
CHEBI:71415 CHEBI
U6Z PDB_CHEM_ID
CHEMBL572 ChEMBL_ID
DB00698 DRUGBANK_ID
CHEMBL1201000 ChEMBL_ID
D009582 MESH_DESCRIPTOR_UI
6604200 PUBCHEM_CID
10917 IUPHAR_LIGAND_ID
488 INN_ID
927AH8112L UNII
221129 RXNORM
181427 MMSL
2320 MMSL
404 MMSL
5179 MMSL
5180 MMSL
5181 MMSL
d00112 MMSL
002852 NDDF
002853 NDDF
002854 NDDF
373543005 SNOMEDCT_US
37978007 SNOMEDCT_US
426476003 SNOMEDCT_US
427332002 SNOMEDCT_US
85343003 SNOMEDCT_US
927AH8112L INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nitrofurantoin Macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 0115-1643 CAPSULE 50 mg ORAL ANDA 25 sections
Nitrofurantoin Macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 0115-1645 CAPSULE 100 mg ORAL ANDA 25 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0115-2023 CAPSULE 50 mg ORAL ANDA 25 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 1 0115-2024 CAPSULE 100 mg ORAL ANDA 25 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 0185-0122 CAPSULE 75 mg ORAL ANDA 25 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 0185-0122 CAPSULE 25 mg ORAL ANDA 25 sections
Nitrofurantoin Macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 0440-1866 CAPSULE 100 mg ORAL ANDA 26 sections
NITROFURANTOIN (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 0615-8531 CAPSULE 75 mg ORAL ANDA 13 sections
NITROFURANTOIN (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 0615-8531 CAPSULE 25 mg ORAL ANDA 13 sections
nitrofurantoin macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 0904-7026 CAPSULE 50 mg ORAL ANDA 13 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 0904-7571 CAPSULE 25 mg ORAL ANDA 14 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 0904-7571 CAPSULE 75 mg ORAL ANDA 14 sections
Nitrofurantoin Monohydrate/ Macrocrystalline HUMAN PRESCRIPTION DRUG LABEL 2 10544-086 CAPSULE 25 mg ORAL NDA 28 sections
Nitrofurantoin Monohydrate/ Macrocrystalline HUMAN PRESCRIPTION DRUG LABEL 2 10544-086 CAPSULE 75 mg ORAL NDA 28 sections
Nitrofurantoin Macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 10544-601 CAPSULE 100 mg ORAL ANDA 24 sections
Nitrofurantion Macrocrystals HUMAN PRESCRIPTION DRUG LABEL 1 12634-415 CAPSULE 100 mg ORAL NDA 24 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 2 13811-719 CAPSULE 75 mg ORAL ANDA 25 sections
Nitrofurantoin HUMAN PRESCRIPTION DRUG LABEL 2 13811-719 CAPSULE 25 mg ORAL ANDA 25 sections
Nitrofurantoin Human Prescription Drug Label 1 16571-740 SUSPENSION 25 mg ORAL NDA AUTHORIZED GENERIC 25 sections
Nitrofurantoin Human Prescription Drug Label 1 16571-740 SUSPENSION 25 mg ORAL NDA AUTHORIZED GENERIC 25 sections
Nitrofurantoin Human Prescription Drug Label 1 16571-888 SUSPENSION 50 mg ORAL NDA AUTHORIZED GENERIC 25 sections
Nitrofurantoin Human Prescription Drug Label 1 16571-888 SUSPENSION 50 mg ORAL NDA AUTHORIZED GENERIC 25 sections
NITROFURANTOIN MACROCRYSTALS HUMAN PRESCRIPTION DRUG LABEL 1 16590-380 CAPSULE 100 mg ORAL ANDA 24 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 16714-439 CAPSULE 25 mg ORAL ANDA 23 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 16714-439 CAPSULE 75 mg ORAL ANDA 23 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 21695-300 CAPSULE 75 mg ORAL ANDA 27 sections
Nitrofurantoin (monohydrate/macrocrystals) HUMAN PRESCRIPTION DRUG LABEL 2 21695-300 CAPSULE 25 mg ORAL ANDA 27 sections
NITROFURANTOIN HUMAN PRESCRIPTION DRUG LABEL 1 31722-491 SUSPENSION 25 mg ORAL ANDA 25 sections
Nitrofurantoin Monohydrate/ Macrocrystalline HUMAN PRESCRIPTION DRUG LABEL 2 33261-160 CAPSULE 75 mg ORAL NDA 28 sections
Nitrofurantoin Monohydrate/ Macrocrystalline HUMAN PRESCRIPTION DRUG LABEL 2 33261-160 CAPSULE 25 mg ORAL NDA 28 sections